Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
M Arcieri, V Tius, C Andreetta, S Restaino… - Frontiers in …, 2024 - frontiersin.org
About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic
instability due to mutation of genes involved in Homologous Recombination (HRD) and such …
instability due to mutation of genes involved in Homologous Recombination (HRD) and such …
[HTML][HTML] Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions
G Caruso, F Tomao, G Parma, M Lapresa… - International Journal of …, 2023 - Elsevier
Poly (ADP-ribose) polymerase inhibitors (PARPi) represent a new standard of care in the
upfront treatment of advanced epithelial ovarian cancer to the point that the vast majority of …
upfront treatment of advanced epithelial ovarian cancer to the point that the vast majority of …
Identification of potentially actionable genetic variants in epithelial ovarian cancer: a retrospective cohort study
C Fieuws, J Van der Meulen, K Proesmans… - NPJ precision …, 2024 - nature.com
Ovarian cancer is the most lethal gynecologic malignancy, mainly due to late-stage
diagnosis, frequent recurrences, and eventually therapy resistance. To identify potentially …
diagnosis, frequent recurrences, and eventually therapy resistance. To identify potentially …
[HTML][HTML] BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges
L Collet, B Hanvic, M Turinetto, I Treilleux… - Frontiers in …, 2024 - frontiersin.org
BRCA1/2 genes are part of homologous recombination (HR) DNA repair pathways in charge
of error-free double-strand break (DSB) repair. Loss-of-function mutations of BRCA1/2 …
of error-free double-strand break (DSB) repair. Loss-of-function mutations of BRCA1/2 …
[HTML][HTML] PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1 …
L Loverix, I Vergote, P Busschaert… - European Journal of …, 2023 - Elsevier
Abstract Background The PAOLA-1/ENGOT-ov25 trial showed improved progression-free
(PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive …
(PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive …
Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer
NL Burdett, MO Willis, A Pandey, S Fereday… - Scientific Reports, 2023 - nature.com
While the introduction of poly-(ADP)-ribose polymerase (PARP) inhibitors in homologous
recombination DNA repair (HR) deficient high grade serous ovarian, fallopian tube and …
recombination DNA repair (HR) deficient high grade serous ovarian, fallopian tube and …
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type
R Buonaiuto, G Neola, A Caltavituro… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
Objective Preclinical studies have emphasized the potential connection between BRCA
specific domains defects and the activity of Poly ADP-ribose polymerase inhibitors (PARPi) …
specific domains defects and the activity of Poly ADP-ribose polymerase inhibitors (PARPi) …
[HTML][HTML] Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
JA Vendrell, IO Ban, I Solassol, P Audran… - International Journal of …, 2023 - mdpi.com
Purpose: The introduction of PARP inhibitors (PARPis) as a treatment option for patients with
high-grade serous ovarian cancer (HGSOC) modified the approach of BRCA testing …
high-grade serous ovarian cancer (HGSOC) modified the approach of BRCA testing …
[HTML][HTML] Homologous recombination deficiency (HRD) scoring, by means of two different shallow whole-genome sequencing pipelines (sWGS), in ovarian cancer …
High-grade serous ovarian cancer (HGSOC) patients carrying the BRCA1/2 mutation or
deficient in the homologous recombination repair system (HRD) generally benefit from …
deficient in the homologous recombination repair system (HRD) generally benefit from …
RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis
A Tsantikidi, K Papazisis, T Floros… - Oncology …, 2023 - spandidos-publications.com
Tumors harboring homologous recombination deficiency (HRD) are considered optimal
candidates for poly (ADP-ribose) polymerase 1 (PARP) inhibitor treatment. Such deficiency …
candidates for poly (ADP-ribose) polymerase 1 (PARP) inhibitor treatment. Such deficiency …